**Introduction** {#Sec1}
================

The Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the treatment of plaque psoriasis. The full version of the Guidelines has been published in the Journal der Deutschen Dermatologischen Gesellschaft (JDDG 2006 Suppl 2) and is available at <http://www.psoriasis-leitlinie.de> \[[@CR149]\]. This article summarizes the key points of the Guidelines.

**Background** {#Sec2}
--------------

Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries is 1.5--2% \[[@CR2]\]. Studies on the impairment of life quality have shown that, depending on the severity of the disease, a significant burden may exist in the form of a disability or psychosocial stigmatization \[[@CR3]\]. Patient surveys have shown that the mental and physical impairment associated with psoriasis is comparable to that of other significant chronic conditions, such as type 2 diabetes or chronic respiratory diseases \[[@CR4]\].

Patient surveys have shown that only 25% of psoriasis patients are highly satisfied with the outcome of their treatment, another 50% indicate moderate satisfaction, and approximately 20% report low treatment satisfaction \[[@CR5]\]. In addition, there is a high non-compliance rate in the intake of medication of up to 40% \[[@CR1]\].

Experience has shown that treatment selection for patients with psoriasis vulgaris is more commonly based on traditional concepts than on evidence-based data on the efficacy of various therapeutic options. In addition, it appears that systemic therapies are occasionally not applied in situations where they are needed due to the increased effort involved in monitoring the patients for unwanted side effects and possible interactions with other drugs.

**Goal of the Guidelines** {#Sec3}
--------------------------

The overall objective of the Guidelines is to provide dermatologists in clinics and private practice with an accepted and evidence-based decision-making tool for the selection and implementation of a suitable and efficacious treatment for patients with psoriasis vulgaris. The focus of the Guidelines is on the induction therapy of mild, moderate, and severe plaque-type psoriasis in adults.Physicians' personal experiences and traditional therapeutic concepts should be supplemented and, if necessary, replaced by an evidence-based assessment of the efficacy of individual therapies in psoriasis vulgaris.The guidelines provide in-depth explanations of the available systemic and topical treatments for psoriasis, including the different photo- and photochemical therapies, and provide detailed descriptions of the administration and safety aspects.By providing background information on the profile of the available drugs, including efficacy, safety, and aspects of practicality and costs, the Guidelines should facilitate the process of selecting an appropriate treatment for each individual patient. This should help increase compliance and optimize the benefit/risk ratio of psoriasis therapies.

**Methods** {#Sec4}
===========

A detailed description of the methodology employed in developing the Guidelines can be found in the Method Report on the Guidelines (<http://www.psoriasis-leitlinie.de>).

**Basis of data** {#Sec5}
-----------------

A systematic search of the literature was carried out in May 2005 with the objective of assessing the effectiveness of individual therapeutic options. This search yielded 6,224 publications of which 142 studies fulfilled the inclusion criteria for the Guidelines (see Box 1) and were therefore included in the assessment of the effectiveness of the relevant treatment. Various other aspects were evaluated on the basis of information presented in available literature, without a systematic analysis, and the years of personal experience of the experts.

**Evidence assessment** {#Sec6}
-----------------------

The efficacy and effectiveness of each intervention was evaluated using evidence-based criteria.

The methodological quality of each individual study was assessed using the following grades of evidence (GE):A~1~Meta-analysis that includes at least one randomized study with grade A~2~ evidence. In addition, the results of the different studies included in the meta-analysis must be consistent with one another.A~2~A high-quality (e.g. sample-size calculation, flow chart, intention-to-treat (ITT) analysis, sufficient size) randomized, double-blind comparative clinical study.BRandomized clinical study of lesser quality or other comparative study (non-randomized, cohort, or case-control study).CNon-comparative study.DExpert opinion.Individual interventions (i.e., as monotherapy) were rated according to the following levels of evidence (LE):Intervention is supported by studies with grade A~1~evidence or studies with grade A~2~ evidence whose results are predominantly consistent with one another.Intervention is supported by studies with grade A~2~ evidence or studies with grade B evidence whose results are predominantly consistent with one another.Intervention is supported by studies with grade B evidence or studies with grade C evidence whose results are predominantly consistent with one another.Little or no systematic empirical evidence

**Therapeutic recommendation** {#Sec7}
------------------------------

A distinct rating of the therapeutic options or a strict clinical algorithm cannot be defined for the treatment of psoriasis vulgaris. The criteria for selecting a particular therapy are complex. The decision for a specific treatment should be based on the profile of the available drugs and the characteristics of a given patient. The decision for or against a therapy remains a case-by-case decision. These Guidelines provide a reasonable form of assistance in deciding on a suitable therapy and are an instrument for optimizing the required therapeutic process.

The recommendations formulated in the text are supported graphically in selected key recommendations by the following indications of the **strength of the therapeutic recommendation**:↑↑Measure is highly recommended↑Measure is recommended→Neutral↓Measure is not recommended↓↓Measure is highly inadvisableThe strength of the recommendation reflects both a treatment's efficacy and the level of evidence supporting it as well as aspects of safety, practicality, and the cost/benefit ratio. A consensus on the strength of the recommendation was reached during the Consensus Conference.

**Results** {#Sec8}
===========

Therapeutic options are named and discussed in alphabetical order.

**Therapeutic strategies** {#Sec9}
--------------------------

![Overview of the therapeutic options evaluated for chronic plaque psoriasis (the therapeutic options are listed alphabetically and do not represent a ranking)](403_2007_744_Fig1_HTML){#Fig1}

**Evaluation of topical and systemic therapies in tabular form** {#Sec10}
----------------------------------------------------------------

These tables are intended to provide a rough orientation for evaluating the therapeutic options. Cumulative calculations of the individual aspects for the overall evaluation of the therapeutic options are not possible and cannot be drawn upon for the final analysis of a therapeutic option. The product assessment for each individual patient may deviate greatly. A direct comparison between systemic and topical therapies is not possible because of the different severity of the psoriasis lesions of patients treated with topical or systemic treatments. The evaluations reported here were made on the basis of data extracted from the literature and expert opinions.

For further details refer to the Methods Report at www.psoriasis-leitlinie.de

### *Topical monotherapy* {#Sec11}

### *Phototherapy and systemic monotherapy* {#Sec12}

\(a\) *Efficacy* The evaluation of the efficacy column reflects the percentage of patients who achieved a reduction in the baseline Psoriasis Area and Severity Index (PASI) of ≥75%. ScaleSystemic therapyTopical therapy++++Approx. 90%Approx. 60%+++Approx. 70%Approx. 45%++Approx. 50%Approx. 30%+Approx. 30%Approx. 15%+/−Approx. 10%Approx. 5%--Not definedNot defined

The evidence level applies only to the estimate of efficacy.

\(b\) *Safety/tolerance in induction therapy or maintenance therapy*This refers to the risk of occurrence of severe adverse drug reactions or the probability of adverse drug reactions that would result in the discontinuation of therapy.

\(c\) *Practicality (Patient)* This evaluation analyzes the effort involved in handling and administrating the treatment regimen by the patient.

\(d\) *Practicality (Physician)* This aspect considers the amount of work (documentation, explanation, monitoring), personnel and equipment needs, time for physician/patient interaction, remuneration of therapeutic measures, invoicing difficulties/risk of recourse claims from the health insurance companies.

\(e\) *Cost/benefit*Consideration of the costs of an induction therapy or a maintenance therapy.

The evaluations of safety/tolerance in induction therapy or maintenance therapy as well as practicality for the physician or patient and the cost/benefit were performed using a scale ranging from poor (--) to good (++++). The gradation between these two extremes was made based on expert opinion and unsystematic literature search. A level of evidence was not given for these evaluations since no systematic literature review was performed.

**Evaluation of topical therapies** {#Sec13}
-----------------------------------

### *Calcineurin inhibitors* {#Sec14}

Table 1Tabular summaryCalcineurin inhibitorsFirst approved in Germany Pimecrolimus (Elidel^®^)2002 (Atopic dermatitis, not approved for psoriasis vulgaris) Tacrolimus (Protopic^®^)2002 (Atopic dermatitis, not approved for psoriasis vulgaris)Recommended initial dosagePimecrolimus cream: 1× to 2× daily\
Tacrolimus: 1× to 2× daily (application on the face: Begin with 0.03% salve; increase later dosage to 0.1% salve)Recommended maintenance dosageIndividual therapeutic adjustmentExpected beginning of clinical effectAfter approximately 2 weeksResponse rateNo data availableImportant contraindicationsPregnancy and nursing (due to lack of experience) skin infections, immune suppressionImportant adverse drug reactions (ADRs)Burning sensation on skin, skin infectionsImportant drug interactionsNone knownOther*Cave: Do not combine with phototherapy! Photoprotection!*

### *Corticosteroids* {#Sec15}

Table 2Tabular summaryCorticosteroidsFirst approved in Germany1956 (Psoriasis vulgaris)Recommended control parametersNoneRecommended initial dosageOne to two times dailyRecommended maintenance dosageGradual reduction following onset of effectExpected beginning of clinical effectAfter 1--2 weeksResponse rateBetamethasone dipropionate, two times daily: marked improvement or clearance of the skin lesions in 46--56% patients after 4 weeks (LE 1)Important contraindicationsSkin infections, rosacea, perioral dermatitisImportant ADRsSkin infections, perioral dermatitis, skin atrophy, hypertrichosis, striaeImportant drug interactionsNoneOther--

### *Coal tar* {#Sec16}

Table 3Tabular summaryCoal tarFirst approved in GermanyListed active ingredient since 2000 (DAC on page 170), historical application, various tar-containing externals are licensed as drugs, application of tar as anti-psoriatic following publication by Goeckermann in 1925Recommended control parametersAfter long-term application/application on large areas: if needed clinical controls for potential development of skin carcinomaRecommended initial dosage5--20% salve preparations or gels for local therapy, 1× dailyRecommended maintenance dosageNo long-term application (max. 4 weeks, DAC 2000)Expected beginning of clinical effectAfter 4--8 weeks, efficacy improves in combination with UV applicationResponse rateThere is insufficient data available on the response rate as a monotherapy (LE 4)Important contraindicationsPregnancy and nursingImportant ADRsColor, odor, carcinogenic risk, phototoxicity---which is part of the desired effectImportant drug interactionsNot known with topical useOtherDAC 2000 (on page 170), Hazardous Goods Directive Appendix 4 No. 13

### *Dithranol* {#Sec17}

Table 4Tabular summaryDithranolFirst approved in GermanyPsoralon1983 (Psoriasis vulgaris)Psoradexan1994 (Psoriasis vulgaris)Micanol1997 (Psoriasis vulgaris)Recommended control parametersIntensity of irritationRecommended initial dosageBegin with 0.5% preparation for long-term therapy or 1% for short-contact therapy, then increase if toleratedRecommended maintenance dosageNot recommended for maintenance therapyExpected beginning of clinical effectAfter 2--3 weeksResponse rateMarked improvement or clearance of skin lesions in 30--50% of the patients (LE 2)Important contraindicationsAcute, erythrodermic forms of psoriasis vulgaris; pustular psoriasisImportant ADRsBurning and reddening of the skin in \>10%Important drug interactions--Other--

### *Tazarotene* {#Sec18}

Table 5Tabular summaryTazaroteneFirst approved in Germany1997 (psoriasis vulgaris)Recommended control parametersCheck development of skin irritationsRecommended initial dosageBegin with one treatment daily of tazarotene gel 0.05% in the evening for approximately 1--2 weeksRecommended maintenance dosageIf necessary continue for 1--2 weeks with tazarotene gel 0.1%Expected beginning of clinical effectAfter 1--2 weeksResponse rateAfter 12 weeks therapy with 0.1% tazarotene gel improved findings of at least 50% in approximately 50% of the patients (LE 2)Important contraindicationsPregnancy, nursingImportant ADRsPruritus, burning sensation of skin, erythema, irritationImportant drug interactionsAvoid concomitant use of preparations with irritating and drying propertiesOther--

### Vitamin D~3~ and analogues {#Sec19}

Table 6Tabular summaryVitamin D~3~ and analoguesFirst approved in Germany Calcipotriol1992 (Psoriasis vulgaris) Tacalcitol1994 (Psoriasis vulgaris) Calcitriol1999 (Psoriasis vulgaris) Calcipotriol/Betamethasone2002 (Psoriasis vulgaris)Recommended control parametersMonitor for skin irritationsRecommended initial dosageCalcipotriol: 1× to 2× daily to affected locations, up to a maximum of 30% of the body surfaceTacalcitol: 1× daily to affected locations, up to a maximum of 20% of the body surfaceCalcitriol: 2× daily to affected locations, up to a maximum of 35% of the body surfaceRecommended maintenance dosageCalcipotriol: 1× to 2× daily, up to 100 g/week for up to 1 yearTacalcitol: 1× daily for 8 weeks, for up to 18 months, on a maximum of 15% of the body surface with up to 3.5 g dailyCalcitriol: insufficient experience with the application for more than 6 weeksExpected beginning of clinical effectAfter 1--2 weeksResponse rateBetween 30 and 50% of the patients demonstrated a marked improvement or clearance of the lesions after 4--6 weeks (LE 1)Important contraindicationsDiseases with abnormal calcium metabolism, severe liver and renal diseasesImportant ADRsSkin irritation (reddening, itching, burning)Important drug interactionsDrugs which elevate the calcium levels, (e.g. thiazide diuretics), no concomitant application of topical salicylic acid preparations (inactivation)OtherExposure to UV light results in inactivation of the vitamin D~3~-analogues

**Phototherapy** {#Sec20}
----------------

Table 7Tabular summaryPhototherapyFirst approved in GermanyClinical experience, depending on the modality for \>50 yearsRecommended control parametersRegular skin inspection (UV erythema)Recommended initial dosageIndividual dose depends on skin type; options:• UVB: 70% of minimum erythema dose (MED)• Oral PUVA (photochemotherapy): 75% of the minimum phototoxic dose (MPD)• Bath/cream PUVA: 20**--**30% of MPDRecommended maintenance dosageIncrease according to degree of UV erythemaExpected beginning of clinical effectAfter 1--2 weeksResponse rateIn \>75% of the patients PASI, 75 after 4--6 weeks (LE 2)Important contraindicationsPhoto-dermatoses/photosensitive diseases, skin malignancies, immunosuppression\
Only PUVA: pregnancy and nursingImportant ADRsErythema, itching, blistering, malignancies\
Only oral PUVA: nauseaImportant drug interactionsDrugs causing phototoxicity or photoallergyOtherCombination with topical preparations acts synergistically, PUVA may not be combined with cyclosporine

**Evaluation of systemic therapies** {#Sec21}
------------------------------------

### *Efalizumab* {#Sec34}

Table 8Tabular summaryEfalizumabFirst approved in GermanySeptember 2004 (psoriasis vulgaris)Recommended control parametersPrior to therapy exclusion of significant infections, complete blood count, liver valuesRecommended initial dosage0.7 mg/kg body weight (BW) per weekRecommended maintenance dosage1 mg/kg BW per weekExpected beginning of clinical effectAfter 4--8 weeksResponse ratePASI 75 for approximately 30% of the patients after 12 weeks (LE 1)Important contraindications (limited selection)Chronic or acute infections, pregnancy, malignant diseases, immune deficiencies, no vaccinations before or during treatmentImportant ADRs (limited selection)Flu-like injection reactions, leukocytosis and lymphocytosis, rebound, exacerbation and arthralgia, thrombocytopeniaImportant drug interactionsNot knownOtherStop therapy due to the risk of exacerbation and rebound if a PASI reduction of 50% is not achieved after 12 weeks

Table 9Laboratory controls during treatment with efalizumab^a^Hb (hemoglobin), HCT (hematocrit), erythrocytes, leukocytes, differential blood count, platelets^b^ALT alanine aminotransferase, AST aspartate aminotransferase

#### *Etanercept* {#Sec24}

Table 10Tabular summaryEtanerceptFirst approved in Germany2002 (Psoriasis arthritis )/2004 (psoriasis vulgaris)Recommended control parametersPrior to therapy exclusion of tuberculosis, complete blood count, liver and renal values, urinanalysisRecommended initial dosageTwice 25 mg per week or 2× 50 mg/weekRecommended maintenance dosageTwice 25 mg per weekExpected beginning of clinical effectAfter 4--8 weeks, at the latest after 12 weeksResponse ratePASI 75 in 34% (2 × 25 mg) or 49% (2 × 50 mg) of the patients at the end of the induction phase (12 weeks) (LE 1)Important contraindications (limited selection)Infections, pregnancy, nursing, heart failure NYHA III--IVImportant ADRs (limited selection)Local reactions, infectionsImportant drug interactions (limited selection)Anakinra (IL-1 receptor antagonist)Other--

Table 11Laboratory controls during treatment with etanercept

#### *Infliximab* {#Sec25}

Table 12Tabular summaryInfliximabFirst approved in Germany2004 (Psoriasis arthritis)/2005 (psoriasis vulgaris)Recommended control parametersPrior to therapy exclusion of tuberculosis, during therapy: leukocyte and platelet counts, liver value controls, signs of clinical infectionRecommended initial dosage5 mg/kg BW at week 0, 2, 6Recommended maintenance dosage5 mg/kg BW in dosage intervals of 8 weeksExpected beginning of clinical effectAfter 1--2 weeksResponse ratePASI 75 in ≥80% of the patients with moderate to severe psoriasis vulgaris (LE 1)Important contraindications (limited selection)Acute or chronic infections, tuberculosis, cardiac failure NYHA III--IV, pregnancy and nursingImportant ADRs (limited selection)Infusion reactions, severe infections, progression of heart failure NYHA III--IV, very rare liver failure, autoimmune phenomenaImportant drug interactions (limited selection)Anakinra (IL-1 receptor antagonist)Other--

Table 13Laboratory controls during treatment with infliximab^a^Hb, HCT, erythrocytes, leukocytes, differential blood count, platelets

### *Cyclosporine* {#Sec26}

Table 14Tabular summaryCyclosporineFirst approved in Germany1983 (Transplantation medicine)1993 (Psoriasis vulgaris)Recommended control parametersInterview/examination:• Status of skin and mucous membranes• Signs of infection• Neurological, gastrointestinal symptoms• Blood pressureLaboratory controls: see Table [14](#Tab14){ref-type="table"}Recommended initial dosage2.5--3 (max. 5) mg/kg BWRecommended maintenance dosageInterval therapy (between 8 and 16 weeks) with dosage reduction at the end of the induction therapy (e.g., 0.5 mg/kg BW every 14 days) orContinuous long-term therapy with dosage reduction (e.g. by 50 mg every 4 weeks after week 12) and a dosage increase by 50 mg with relapseMaximum total duration of therapy: 2 yearsExpected beginning of clinical effectAfter approximately 4 weeksResponse rateDose-dependent: after 8--16 weeks with 3 mg/kg BW; PASI 90 in approximately 30--50% of patient and PASI 75 in approximately 50--70% of patients (LE 1)Important contraindications (limited selection)**Absolute**:Reduced renal function, insufficiently controlled arterial hypertension, uncontrolled infections, relevant malignancies (current or previous, in particular hematologic diseases and cutaneous malignancies with the exception of basal cell carcinoma)**Relative:**Relevant hepatic dysfunction, pregnancy and nursing, concomitant use of substance which interacts with cyclosporine, concomitant UV-therapy or prior PUVA-pre-therapy with cumulative dosage \>1000 J/cm², concomitant application of other immunosuppressives, retinoids or long-term prior-therapy with methotrexate (MTX)Important ADRs (limited selection)Renal failure, increase of blood pressure, liver failure, nausea, anorexia, vomiting, diarrhea, hypertrichosis, gingival hyperplasia, tremor, weariness, parasthesia, hyperlipidemiaImportant drug interactions (limited selection)Increase of the cyclosporine level (CYP3A inhibition) through:Allopurinol, calcium antagonists, amiodarone, antibiotics (macrolides, clarithromycin, josamycin, ponsinomycin, pristinamycin, doxycycline, gentamicin, tobramycin, ticarcillin, quinolones), ketoconazole, oral contraceptives, methylprednisolone (high dosages), ranitidine, cimetidine, grapefruit juiceDecrease of the cyclosporine level (CYP3A induction) through: Carbamazepine, phenytoin, barbiturates, metamizole, St. John's wortPossible reinforcement of nephrotoxic adverse drug reactions through: Aminoglycosides, amphotericin B, ciprofloxacin, acyclovir, non-steroidal antiphlogisticsSpecific interactions:Potassium-saving substances: increased risk of hyperpotassemiaReduced clearance of: Digoxin, colchicine, prednisolone, HMG-CoA reductase inhibitors (e.g. lovastatin), diclofenacOtherIncreased risk of lympho-proliferative diseases in transplant patients. Increased risk of squamous cell carcinoma in psoriasis patients following excessive phototherapy.Only moderately effective in and not approved for psoriatic arthritisAlso used successfully in the therapy of chronic-inflammatory diseases in children

Table 15Laboratory controls during treatment with cyclosporine^a^Erythrocytes, leukocytes, platelets^b^ALT, AST, AP (alkaline phosphatase), γGT (gamma glutamyl transpeptidase), bilirubin^c^Sodium, potassium^d^Recommended twice (fasting) and week-2 and 0^e^Only with indication (e.g. muscle cramps)

### *Fumaric acid esters* {#Sec27}

Table 16Tabular summaryFumaric acid estersFirst approved in Germany1995 (Psoriasis vulgaris)Recommended control parametersSerum creatinine, transaminases/γGT, complete blood count including differential blood count, urinanalysisRecommended initial dosageAccording to recommended dosage regimen see Table [17](#Tab17){ref-type="table"}Recommended maintenance dosageIndividually adapted dosageExpected beginning of clinical effectAfter approximately 6 weeksResponse ratePASI 75 in 50--70% of the patients at the end of the induction phase after 16 weeks (LE 2)Important contraindications (limited selection)Chronic diseases of the gastrointestinal tract and/or the kidneys and chronic diseases, which are accompanied by an impairment of the leukocyte count or functions, malignant diseases, pregnancy and nursingImportant ADRs (limited selection)Gastrointestinal complaints, flush, lymphopenia, eosinophiliaImportant drug interactionsNone knownOther--

Table 17Dosage regimen for Fumaderm therapyFumaderm initialFumadermWeek 11-0-0Week 21-0-1Week 31-1-1Week 41-0-0Week 51-0-1Week 61-1-1Week 72-1-1Week 82-1-2Week 92-2-2

Table 18Laboratory controls during treatment with fumaric acid esters^a^Leukocytes, platelets, erythrocytes, differential blood count

### *Methotrexate* {#Sec28}

Table 19Tabular summaryMethotrexateFirst approved in Germany Lantarel^®^1991 (Psoriasis vulgaris) Metex^®^ 7.5/10 mg1992 (Psoriasis vulgaris) Metex^®^ 2.5 mg2004 (Psoriasis vulgaris)Recommended control parametersComplete blood count (Hb, HCT, differential blood count, platelets), renal function (serum creatinine, urea, urine sediment), liver values (serum transaminases), III-procollagen amino terminal propeptidesRecommended initial dosage5--15 mg per weekRecommended maintenance dosage5--22.5 mg per week depending on effectExpected beginning of clinical effectAfter 4--8 weeksResponse ratePASI 75 in approximately 60% of the patients at the end of the induction phase of 16 weeks (LE 3)Important contraindications (limited selection)**Absolute contraindications**:Desire to have children (for both men and women), pregnancy and nursing, inadequate contraception, drug consumption, alcoholism, known sensitivity to active ingredient methotrexate (e.g. pulmonary toxicity), bone marrow dysfunction, severe liver disease, severe infections, immunodeficiency, active peptic ulcers, hematologic changes (leucopenia, thrombocytopenia, anemia), renal failure**Relative contraindications**:Kidney disorders, liver disorders, history of arsenic consumption , chronic congestive cardio-myopathy, adiposity, old age, diabetes mellitus, history of hepatitis, lack of patient compliance, ulcerative colitis, diarrhea, NSAID use, gastritisImportant ADRs (limited selection)Liver fibrosis/cirrhosis, pneumonia/alveolitis, bone marrow depression, renal damage, alopecia (reversible), nausea, weariness, vomiting, elevated transaminases, infection, gastrointestinal ulcerations, nephrotoxicityImportant drug interactions (limited selection)Cyclosporine, salicylates, sulfonamides, probenecide, penicillin, colchicin, NSAIDs (naproxene, ibuprofene, etc.), ethanol, co-trimoxazole, pyrimethamine, chloramphenicol, sulfonamides, prostaglandin synthesis inhibitors, cytostatics, probenecide, barbiturates, phenytoin, retinoids, sulfonamides, sulfonylurea, tetracyclines, co-trimoxazol, chloramphenicol, dipyridamole, retinoids, ethanol, leflunomideOtherConsistent avoidance of alcohol, X-ray of the lungs prior to beginning therapy

Table 20Laboratory controls during treatment with MTX \[[@CR137]\]^a^Hb, HCT, erythrocytes, leukocytes, differential blood count, platelets^b^ALT, AST, AP, γGT, albumin, bilirubin, lactate dehydrogenase (LDH)^c^Liver biopsy instead of a liver sonography in risk groups

### *Retinoids* {#Sec29}

Table 21Tabular summaryAcitretinFirst approved in Germany1992 (Psoriasis vulgaris)Recommended control parametersErythrocyte sedimentation rate (ESR), complete blood count, liver values, renal values, blood lipid values, pregnancy test, x-ray control of the bones in case of long-term therapyRecommended initial dosage0.3--0.5 mg/kg BW per day for approximately 4 weeks, then 0.5--0.8 mg/kg BWRecommended maintenance dosageIndividual dosaging dependent on the results and toleranceExpected beginning of clinical effectAfter 4--8 weeksResponse rateWidely variable and dose-dependent, no definite statement possible, partial remission (PASI 75) in 25--75% of the patients (30--40 mg per day) (LE 3) in studiesImportant contraindications (limited selection)Renal and liver damage, desire to have children in female patients of child-bearing age, pregnancy, nursing, alcohol abuse, manifest diabetes mellitus, wearing of contact lenses, history of pancreatitis, hyperlipidemia requiring drug treatmentImportant ADRs (limited selection)Hypervitaminosis A (e.g., cheilitis, xerosis, nose-bleeding, alopecia, increased skin fragility)Important drug interactions (limited selection)Phenytoin, tetracyclines, methotrexate, alcohol, mini-pillOtherContraception up to 2 years after discontinuation in female patients of child-bearing age

^a^Double contraception is recommended (e.g., condom + pill; IUD/Nuva-Ring + pill; cave: no low-dosed progesterone preparations/mini-pills) during and up to 2 years after the end of therapy; effectiveness is reduced by acitretin

Table 22Laboratory controls during treatment with Acitretin^a^Hb, HCT, leukocytes, platelets^b^Preferably assayed twice (week-2 and 0); HDL, high-density lipidoprotein

**Other therapies** {#Sec30}
-------------------

### *Climate/balneotherapy* {#Sec31}

Table 23Tabular summaryClimate/balneotherapyFirst approved in GermanyClinical experience with balneotherapy has existed for more than 200 yearsRecommended control parametersRegular skin inspectionRecommended initial dosageTherapy regimens vary depending on the institution/locationRecommended maintenance dosageTherapy regimens vary depending on the institution/locationExpected beginning of clinical effectVaries greatlyResponse rateVaries greatly (LE 4)Important contraindicationsDependent on modality selectedImportant ADRsDependent on modality selectedImportant drug interactionsNot applicableOtherBalneotherapy and climate therapy are frequently combined

### *Psychosocial therapy* {#Sec32}

Notes on the use of the Guidelines {#Sec33}
==================================

The presentation of the therapies deliberately focused on those aspects deemed particularly relevant by a panel of experts. Aspects which are not of specific importance for a certain intervention, but which are part of the physician's general obligations to the patient, such as the investigation of intolerance and allergies toward certain drugs or the exclusion of contraindications, are not individually listed, but it is nevertheless taken for granted that these are part of the physician's duty to provide care.

It is recommended that each and every user carefully reads and follows the product information and compare it with the recommendations in the Guidelines on dosaging, contraindications, and drug interactions for completeness and currentness. Every dose or application is administered at the user's own risk. The authors and the publishers kindly request that users inform them of any inaccuracies that they might notice. The users are requested to keep themselves constantly informed of any new findings subsequent to the publication of the Guidelines.

The guidelines were generated upon request by the Deutsche Dermatologische Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD). The project was supported by the 'Förderverein der Deutschen Dermatologischen Gesellschaft', the funding body of the DDG.
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An enhanced version of these guidelines has been published with Blackwell in 2006.
